AYTU BIOSCIENCE, INC. - Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed by AYTU BIOSCIENCE, INC. on January 20, 2016. The report details a private placement of equity securities and the resulting triggering of conversion rights for existing convertible note holders.
Key Financial Metrics and Transactions
- Equity Financing: The company sold 307,692 shares of common stock (153,846 shares each) to CEO Joshua R. Disbrow and COO Jarrett T. Disbrow.
- Price per Share: $0.65.
- Gross Proceeds: $199,999.80.
- Existing Debt: The company has outstanding convertible promissory notes with an aggregate principal amount of $5,175,000 issued in July and August 2015.
- Liquidity Impact: The transaction provided immediate cash proceeds of approximately $200,000.
Material Changes and Triggering Events
The sale of common stock at $0.65 per share triggered a specific provision in the outstanding convertible notes. While this transaction does not constitute a "Qualified Financing" (which requires $5,000,000 in gross proceeds), it activated an optional conversion right for noteholders.
- Conversion Option: Noteholders have the option to convert their entire outstanding principal and accrued interest into common stock.
- Conversion Terms: The conversion price is based on the $0.65 share price paid by the officers, with a 120% discount (effectively converting at a price of $0.5417 per share).
- Timeline: Noteholders have 10 business days from receipt of notice to exercise this option.
Outlook, Risks, and Management Commentary
The filing does not provide forward-looking guidance, revenue projections, or management commentary regarding future operations. The primary risk disclosed is the potential dilution of existing shareholders if noteholders exercise their conversion option at the discounted rate. The company explicitly states that the notice to noteholders is not a recommendation to exercise the option.
Key Facts for Investor Verification
- Verify the total number of shares outstanding post-transaction and the potential dilution if all $5,175,000 in notes are converted at the $0.65 price point.
- Confirm whether the $200,000 in proceeds is sufficient to meet immediate operational cash flow needs.
- Review the full terms of the convertible notes (Exhibit 4.1) to understand the maturity date and interest accrual rates.
- Monitor subsequent filings to determine if noteholders elected to convert their debt into equity.